Browse Prior Art Database

oral pharmaceutical formulations for antidepressant

IP.com Disclosure Number: IPCOM000011778D
Publication Date: 2003-Mar-14
Document File: 1 page(s) / 53K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a Microsoft Word document.
At least one non-text object (such as an image or picture) has been suppressed.
This is the abbreviated version, containing approximately 81% of the total text.

Oral Pharmaceutical Formulations for Antidepressant

Sustained or controlled release oral dosage forms capable of releasing 25mg to 250mg of the active pharmaceutical ingredient represented by the chemical formula shown in Figure 1, optionally in the form of its hydrochloride salt, to human patients over extended periods following administration may contain the following active and inactive ingredients: 15% to 25% of the active pharmaceutical ingredient represented by the chemical formula shown in Figure 1, optionally in the form of its hydrochloride salt, 10% to 30% of an anionic acrylic copolymer e.g. which conforms to USP/NF specifications of USP methacrylic acid copolymer type B, 35% to 65% of a calcium hydrogen phosphate, 4% to 10% of a carboxyvinyl polymer included as a release-rate controlling agent e.g. carbomer 71G, 3% to 7% of a polyvinyl alcohol and from 0.01% to 3% of other conventional tabletting excipients e.g. known lubricants, opacifiers, glidants and/or anti-caking agents.

Figure 1.

Said dosage forms may be administered or further processed in granulate, tablet or powder form as solid solutions, solid dispersions or mixtures thereof.  Any known and as-yet undisclosed formulation methods may be used as-is or adapted in any manner to arrive at the formulations disclosed herein.

Where coating methods are to be applied to any dosage form, it is envisaged that the required solution or suspension may be formulated by preparing an aqueous solution comprising polymer...